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Introduction: In previous studies, we successfully designed complex multicompartmental 
microcapsules as a platform for the oral targeted delivery of lipophilic drugs in type 2 diabetes 
(T2D). Probucol (PB) is an antihyperlipidemic and antioxidant drug with the potential to 
show benefits in T2D. We aimed to create a novel microencapsulated formulation of PB and 
to examine the shape, size, and chemical, thermal, and rheological properties of these micro-
capsules in vitro.
Method: Microencapsulation was carried out using the Büchi-based microencapsulating 
system developed in our laboratory. Using the polymer, sodium alginate (SA), empty (control, 
SA) and loaded (test, PB-SA) microcapsules were prepared at a constant ratio (1:30). Complete 
characterizations of microcapsules, in terms of morphology, thermal profiles, dispersity, and 
spectral studies, were carried out in triplicate.
Results: PB-SA microcapsules displayed uniform and homogeneous characteristics with an 
average diameter of 1 mm. The microcapsules exhibited pseudoplastic-thixotropic characteristics 
and showed no chemical interactions between the ingredients. These data were further supported 
by differential scanning calorimetric analysis and Fourier transform infrared spectral studies, 
suggesting microcapsule stability.
Conclusion: The new PB-SA microcapsules have good structural properties and may be suit-
able for the oral delivery of PB in T2D. Further studies are required to examine the clinical 
efficacy and safety of PB in T2D.
Keywords: artificial cell microencapsulation, diabetes, antioxidant, anti-inflammatory, 
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Introduction
Diabetes mellitus (DM) is a metabolic disorder that affects millions of people globally. 
The prevalence of DM is increasing worldwide at an alarming rate because of lifestyle 
changes, aging, urbanization, increasing obesity, and physical inactivity.1,2 DM is clas-
sified mainly as type 1 diabetes (T1D) or type 2 diabetes (T2D).3 T2D develops because 
of genetic and environmental factors that lead to tissue desensitization to insulin.4 
Antidiabetic drugs are commonly used and are effective in minimizing variations 
between peaks and troughs of blood glucose levels in diabetic patients. However, β cell 
damage, coupled to the build-up of free radicals and toxins, remain detrimental factors 
in the treatment of the disease and its complications.5 Thus, there is a real need for new 
and more efficacious medications for diabetes, which are capable of exerting a stronger 
protection of β cells and have substantial anti-free radical and antioxidant effects.
Probucol (PB) (Sigma-Aldrich Co., St Louis, MO, USA) is a highly lipophilic (dis-
sociation constant, pk
a
=10.24) drug that has been shown to protect β cells of the pancreas 





through its strong anti-free radical and antioxidant effects, 
thereby neutralizing reactive oxygen species and alleviating 
oxidative stress.6,7 PB was developed as an antihyperlipidemic 
drug but was withdrawn in some countries because of high 
interindividual variation in absorption and potentially severe 
adverse effects.8 PB is still in use in a few countries, mainly for 
familial hypercholesterolemia in combinations with statins. 
PB accumulates extensively in adipose tissues and is primarily 
eliminated via the fecal route.9 PB’s elimination half-life is 
highly variable between individuals and is estimated to range 
from 23 to more than 50 days. An early study reported that 
hypercholesterolemic patients treated with PB were found to 
have plasma levels of PB averaging 98 µM.10 Peak plasma 
concentrations are also significantly variable, and the time 
to reach maximum concentration in plasma is between 8–24 
hours after an oral dose.
PB concentrations in adipose tissues are 100 times 
higher than that in plasma, resulting in multicompartmental 
distribution and multiphasic excretion pathways.11,12 The 
exact metabolic fate of PB is unknown, but several com-
pounds have been identified in the plasma, although its exact 
biotransformation pathways remain elusive.13 As the major 
route of elimination is the bile and feces, renal clearance is 
very low (2%).13,14 In one study, gelatin-acacia microcapsules 
were prepared by using a special coacervation method and 
were studied for encapsulating microdroplets of oil solu-
tion containing PB; this resulted in better bioavailability.15 
PB’s low and variable oral bioavailability, and its nonlinear 
distribution and clearance, contribute to the variability in its 
pharmacokinetic (PK) and pharmacodynamic properties, as 
well as its adverse effects.16,17 Thus, despite its huge poten-
tial, its variable and poor absorption kinetics remain major 
obstacles to its potential use in T2D.16
Designing a novel and stable formulation with good rheo-
logical parameters is anticipated to overcome these obstacles. 
This can be achieved by using artificial cell microencapsula-
tion (ACM) technology.
Since the innovation of ACM technology by Thomas 
Chang at McGill University in Canada in the 1960s, this 
technology has been used worldwide by many research-
ers,  scientists, and translational entrepreneurs, using bio-
degradable polymers such as sodium alginates. ACM has 
been used significantly in the delivery of various cells and 
therapeutics.18,19 ACM is commonly used to improve the 
delivery of lipophilic drugs that exhibit low bioavailability 
and poor dissolution and absorption kinetics.20 In the pro-
cess of microencapsulation, the microcapsules encapsulate 
a drug using a biodegradable polymer (such as sodium 
alginate), which protects it from the hostile environment 
of the gastrointestinal tract, and provides a pH-sensitive 
targeted delivery. The choice of a polymer has a significant 
effect on the formulation properties and efficacy, as well as 
on the drug’s chemical and thermal characteristics.21 Previ-
ous work by our research group20,22–29 on the formulation 
of the antidiabetic drug gliclazide, alone or combined with 
bile acids (in vitro and in vivo), and our recently designed 
and formulated microcapsules platform have demonstrated 
improved PK and pharmacodynamic responses when using a 
sodium alginate-based formulation. Thus, this study aimed to 
examine the suitability of our newly developed microcapsules 
in producing a novel and a stable PB formulation suitable for 
oral delivery in T2D.
Materials and methods
Materials
PB (98%) and low-viscosity sodium alginate (LVSA, 99%) 
were purchased from Sigma-Aldrich Co., St Louis, MO, USA. 




0, 98%) was obtained 
from Scharlab SL (Barcelona, Spain). All solvents and reagents 
were supplied by Merck & Co, Inc. (Whitehouse Station, NJ, 
USA) and were of high-performance liquid chromatography 
(HPLC) grade and used without further purification.
Drug preparations
Stock suspensions of PB (20 mg/mL) were prepared by add-
ing the powder to 10% ultra water-soluble gel of 100 mL 
HPLC water. The gel is an ultrasonic gel mixed in HPLC 
water. The CaCl
2
 stock solution (2%) was prepared by add-
ing CaCl
2
 dihydrate to HPLC water. All preparations were 
mixed thoroughly at room temperature for 4 hours, stored in 
the refrigerator, and used within 48 hours of preparation.
Preparation of microcapsules
Microcapsules of PB-loaded LVSA were prepared with a 
Büchi-based microencapsulating system (Büchi Labortechnik, 
Flawil, Switzerland), using a jet-flow microencapsulation 
technique, as described elsewhere.28 Parameters were set 
in a frequency range of 1,000–1,500 Hz and a flow rate of 
4 mL/minute under a constant air pressure of 300 mbar. 
Polymer solutions containing LVSA with or without PB were 
made up to a final concentration (of PB-SA) in a ratio of 
1:30.23 Microcapsules were fabricated in the form of hydrosol 
mixture, and for each formulation (unloaded and PB loaded), 
three independent batches were prepared and tested separately 
(n=3). All microcapsules (of both formulations) were prepared 
and treated in the exact same way. Microcapsules were dried 
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by using the Stability Chambers (Angelantoni Environmental 
and Climatic Test Chamber, Massa Martana, Italy).
characterization of PB-loaded 
microcapsules
Morphology, size analysis, and chemical 
characterization of microcapsules
All microcapsules were freshly made, stored in the 
refrigerator, and used within 48 hours of preparation. The 
appearance and size of microcapsules were examined using 
light microscopy, followed by scanning electron microscopy 
and energy-dispersive X-ray spectrometry (EDXR). The 
particle size distribution and mean particle size diameter 
were calculated using the instruments’ software  provided. 
 Membrane width was measured via microcapsule’s 
cross-section measurements, using the mounted ToupTek 
 (Zhejiang, People’s Republic of China) photonics FMA050 
fixed calibrated microscope adaptor.
Optical microscopy
Morphological characteristics and particle size analysis were 
determined using a Nikon YS2-H (Tokyo, Japan) mounted 
with a ToupTek photonics FMA050 fixed calibrated micro-
scope adaptor. Sample analysis was carried out in triplicates. 
Briefly, predetermined quantities (10 microcapsules from 
each formulation) of freshly prepared microcapsules were 
loaded onto a glass slide mounted to a calibrated scale. 
Optical microscopy software (ToupTek) capable of particle 
size analysis, microcapsule characterization, and morphologi-
cal assessments was used to determine basic characteristics 
of the microcapsules to complement the scanning electron 
microscopy (SEM) studies.
seM and eDXr spectroscopy
The surface morphology of the microcapsules was examined 
using SEM (Neon 40EsB FIB-SEM; Zeiss, Oberkochen, 
Germany) with 0.8 nm calibrated resolution. The chemical 
characterization of the microcapsules was examined using 
EDXR (INCA X-Act; Oxford Instruments, Abingdon, 
United Kingdom). Electron micrographs of PB-loaded 
microcapsules and empty SA microcapsules were obtained 
using SEM, and their chemical characterization was obtained 
using EDXR. The samples were mounted on a glass stub with 
double-sided adhesive tape and coated under vacuum with 
platinum (5 nm) in an argon atmosphere before examination. 
Micrographs with different magnifications were recorded to 
study the morphological and surface characteristics of the 
microcapsules.
Determination of dispersing media viscosity
Viscosities of both preparations (SA and PB-SA) were 
measured for freshly prepared mixtures, using 15 mL 
aliquots (n=3) at room temperature and using Visco-88 
viscometry (Bohlin-Visco 88; Malvern Instruments). The 
temperature remained constant at 23°C (monitored by the 
Visco 88).
Differential scanning calorimetric analysis
Differential scanning calorimetry (DSC) thermograms of 
PB, LVSA powder (a physical powder mixture of PB and 
LVSA), and PB-loaded microcapsules were carried out in 
a DSC instrument (DSC 8000; PerkinElmer Inc., Waltham, 
MA, USA). Briefly, 5 mg samples were placed in sealed 
aluminium pans and heated at 20°C/minute under a nitrogen 
atmosphere (flow rate, 30 mL/minute) in the 35°C–240°C 
range. An empty aluminium pan was used as a reference. 
The equipment was calibrated for baseline and temperature, 
using zinc metal.
Fourier transform infrared spectral studies
Fourier transform infrared (FTIR) spectra of pure compo-
nents, their physical mixture, and the PB-loaded microcap-
sules were recorded via attenuated total reflectance FTIR 
spectrometer TWO (PerkinElmer), and infrared measure-
ments were performed in transmission in the scanning range 
of 650–4,000 cm−1 at room temperature. The PB:polymer 
ratio to those analytically determined in the microcapsules 
was used for preparing the different physical mixtures that 
were used as control.
Results and discussion
Morphology, size analysis, and chemical 
characterization of microcapsules
Microcapsules were obtained using LVSA polymer and PB 
at a constant ratio of 1:30. The mean diameters ranged from 
1,100–1,295 µm for all batches of the formulation. The aver-
age size was slightly above 1,000 µm in diameter, rendering 
them macroparticles.
Optical microscopy
A predetermined amount of microcapsules from the SA and 
PB-SA formulation was selected for particle size and mor-
phological analysis. Microcapsules revealed uniform consis-
tency and spherical shapes with similar sizes, as determined 
via a calibrated scale mounted onto a glass slide. The mean 
diameter of PB microcapsules (average ± standard deviation) 
was 1,195±98 µm (Figure 1). The vertical diameter (L1) and 





horizontal diameter (L2) were also measured, along with 
membrane width (L3, L4, and L5), as shown in Figure 1.
seM
Results from optical microscopy revealed opaque, discrete, 
and spherical microcapsules with homogeneous particle size 
 distribution. This was further supported by SEM studies of 
the PB microcapsule (Figures 2 and 3), which represented 
randomly selected microcapsules from a few batches using 
200, 10, 3, and 2 µm scales. Figure 3B and 3D had close 
magnifications, but because of the different angles used, they 
showed different morphology. In addition, SEM results show 








Figure 1 Probucol microcapsules (A) and sodium alginate microcapsule (B).
Notes: l1 and l2 are vertical diameter and horizontal diameter, and l3, l4, and l5 are membrane width thickness at different positions of the microcapsules, respectively. 
Probucol manufactured by sigma-aldrich co., st louis, MO, Usa.
Figure 2 scanning electron micrographs.
Notes: sodium alginate microcapsule at 200 µm scale (A); surface morphology at 2 µm scale (B), 10 µm scale (C), and 3 µm scale (D).
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microcapsules of consistent uniformity and well-defined spher-
ical shapes. Because of the high-resolution images, we were 
able to conclude that the surfaces of the microcapsules were 
rough but consistent from one microcapsule to another in all 
analyzed batches. Interestingly, small crystals were distributed 
throughout the microcapsule surfaces, either as large clumps 
or as smaller ones. These crystals coating the microcapsule 
surface were believed to be the drug, PB, which was confirmed 
by EDXR results (Figures 4, 5, and 7). However, PB present 
in the surface could be crystal or amorphous phase.
eDXr
To further analyze the composition of the microcapsule sur-
face, EDXR was used to identify the various surface crystal 
Figure 3 scanning electron micrographs.
Notes: Probucol-sodium alginate microcapsule at 200 µm scale (A); surface morphology at 2 µm scale (B), 10 µm scale (C), and at 3 µm scale (D). Probucol manufactured 




















Full scale 1,053 cts cursor: 5.958 (5 cts) Full scale 1,573 cts cursor: −0.155 (0 cts)
1 2 3 4 5 6 7 8 9 10
keV
0 1 2 3 4 5 6 7 8 9 10
keV
200 µm
Figure 4 energy-dispersive X-ray spectra of sodium alginate microcapsules’ surface.
Notes: showing crystal deposition (A, 1) and surface composition (C, 2), with corresponding analysis (B and D). note that no sulfur atoms were detected because no 
Probucol was in this formulation.





depositions and microcapsule surface composition. The coat-
ing materials (Pt and Zr) have been neutralized in the analysis 
by the instrument. Analysis of crystal depositions on the 
microcapsule surfaces (Figures 4 and 5) revealed high levels 
of sulfur atoms, confirming that the small crystals noted on 
the surface of PB-SA microcapsules were that of PB (as no 
other compound used in the formulation contains the sulfur 
atom).30 It appears from SEM coupled with EDXR analyses 
that PB preferentially coats the microcapsule surface, form-
ing scattered clumps of drug agglomerates distributed around 
the microcapsule surface.
EDXR assessment for two different surface sites of a SA 
microcapsule is shown in Figure 4, with its corresponding 
analysis. As can be seen, the surface is largely made up of 
calcium and oxygen atoms, which is expected for micro-
capsules produced using the ionic gelation method (surface 
composition is largely calcium alginate).
An example of an EDXR assessment of PB-SA 
microcapsules is shown in Figure 5, with the respective 
spectrum of the microcapsule surface. The microcapsule 
surfaces were not perfectly homogeneous, and thus, vary-
ing crystal depositions occurred at selected sites across 
the microcapsule surface. Figure 5 shows typical PB-SA 
microcapsule surface sites where EDXR analysis was con-
ducted (two distinct sections of the microcapsule surface). 
Two  different sites were randomly selected and analyzed 
( Figures 4A, 4C, 5A and 5C), and the atom composition 
results (Figures 4B, 4D, 5B and 5D) represent both crystals 
of drug agglomerates, as well as the surface itself. The spec-
tra of chemical analysis showed the dominant atoms (Na, O, 
Ca, S, and Cl) we expected for a typical PB-SA microcapsule 
prepared via ionic-gelation methodology. The sulfur atom 
was unique to PB, which showed preferential binding to 
the microcapsule surface; Na and Cl represented sodium 
chloride, which was the byproduct of ionic gelation and 
Ca with O, and was expected, given that the microcapsule 
surface is composed largely of calcium alginate.31,32
Viscosity of the microencapsulated 
formulation
Table 1 shows the viscosity, shear rate, shear stress, and 
torque force for both microencapsulated formulations (SA 
and PB-SA) under various speeds (20, 35, 61, 107, 187, 
327, 572, and 1,000 rpm). No detectable viscosity, torque, 
or shear stress for the SA formulation was found because the 
instrument and/or parameters used were not able to detect 
a significant rheological pattern, despite increasing stirring 
speeds and shear rate. This is similar to previously published 
work using the antidiabetic drug, gliclazide, microencapsu-
lated in SA.28 However, it was noted that the PB-SA formu-
lation behaved in a non-Newtonian, thixotropic manner, as 
made evident by parallel reductions in the apparent viscosity 
with increasing stirring speeds, which was expected.33,34 
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Figure 5 energy-dispersive X-ray spectra of Probucol-sodium alginate microcapsules surface.
Notes: Drug deposition (A, 1) and surface composition (C, 2) with corresponding analysis (B and D). The presence of drug crystals and corresponding sulfur atoms detected 
confirm the presence of Probucol in this formulation. Probucol manufactured by Sigma-Aldrich Co., St Louis, MO, USA.
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of the PB-SA formulation can be seen in the proportional 
increases in torque and shear rate after rising shear stress 
forces and an associated decrease in the viscosity character-
istic of non-Newtonian fluids and thixotropic behavior of the 
polymer solutions.35,36 The flow behavior of the microcapsules 
is important when estimating their PK and pharmacodynamic 
parameters in terms of transit time and pH-targeted delivery 
after an oral dose.27,32 The application of the stirring rod in 
both solutions at increasing speeds resulted in the solu-
tions forming rapid circular motions away from the site of 
centripetal force origin, suggesting they behaved in a non-
Weissenberg fashion.37,38
Dsc
DSC is an important technique for the thermal character-
ization of various materials.39 DSC establishes a connec-
tion between temperature and specific physical properties 
of substances.40,41 It is commonly used to determine the 
enthalpy associated with the process of microencapsulation. 
In microencapsulation, DSC measures how physical proper-
ties of PB molecules change, along with temperature against 
time.42 This occurs through determining the temperature and 
heat flow (35°C–240°C) associated with PB transitions as a 
function of time. DSC spectra were analyzed for PB powder 
(Figure 6A), SA powder (Figure 6B), PB-SA microcapsules 
(Figure 6C), and the combined physical powder mixture 
PB-SA (Figure 6D).
PB has at least two polymorphs with different crystal 
lattice structures and molecular configurations.43,44 Form I 
(melting point, 125°C) is substantially more thermodynami-
cally stable than form II (melting point, 116°C).44 DSC 
analysis of PB powder (Figure 6A) shows a peak of 128°C, 
which is indicative of the melting point of the compound, in 
accordance with published work.45 Importantly, we were able 
to conclude that the PB sample acquired from our supplier was 
form I and not form II. The thermogram of sodium alginate 
powder was also in line with previously published work and 
was indicative of the polymer’s melting point.46 For the com-
bined physical powder mixture, the thermogram included both 
the PB melting peak and that of the polymer, which indicated 
that SA retained its amorphous polymer structure and PB’s 
crystalline form and was not modified on physical mixing. 
The DSC analysis of the PB-SA microcapsules (Figure 6C) 
revealed two distinct peaks. The peak at 127°C clearly depicts 
PB, whereas the peak at 213°C was a marginal shift to the 
right when compared with SA powder (193°C, as seen in 
Figure 6B) and could represent plasticization of the polymer.46 
PB was not chemically modified by and did not participate 
in any reaction with the polymer used in the formulation, as 
evident by endothermic peaks characteristic of the drug after 
analysis of the microcapsules. After microencapsulation, PB 
retained its chemical integrity and crystal lattice structure, 
as confirmed by both DSC and FTIR results (Figure 7); thus, 
full compatibility was evident. In addition, PB form I was 
Table 1 Viscosities and related parameters of both microencapsulated formulations, sodium alginate and Probucol-sodium alginate (n=3)
Formula code  
and set speed
RPM Viscosity,  
mPa × seconds







 1 20 UD 23.8±0.2 UD UD
 2 35 UD 42.1±0.5 UD UD
 3 61 UD 74.4±0.3 UD UD
 4 107 UD 125±0.2 UD UD
 5 187 UD 222±0.3 UD UD
 6 327 UD 385.8±0.2 UD UD
 7 572 UD 681.8±0.1 UD UD
 8 1,000 UD 1,197±3 UD UD
Probucol-sodium alginate
 1 20 UD 23.9±0.3 UD UD
 2 35 UD 42.2±0.3 UD UD
 3 61 UD 74.5±0.2 0.08±0.01 UD
 4 107 25±0.2 125.1±0.2 0.11±0.01 3.2±0.02
 5 187 20±0.2 222.2±0.4 0.17±0.02 4.5±0.01
 6 327 15±0.3 385.7±0.3 0.21±0.03 5.7±0.03
 7 572 10±0.2 681.8±0.1 0.26±0.02 6.9±0.1
 8 1,000 9±0.3 1,194±4 0.40±0.03 10.9±0.01
Note: Probucol manufactured by sigma-aldrich co., st louis, MO, Usa.
Abbreviations: UD, undetected (below the instrument limit of detection); rPM, revolutions per minute.





maintained throughout the microencapsulation procedure, and 
thus, thermodynamic stability was also maintained.
The two distinct peaks detected on the DSC analysis of 
PB-SA microcapsules and PB-SA powder (Figure 6D; one 
for Probucol and the other being alginate) raise the notion 
that the drug was not solubilized in the matrix system of the 
microcapsules; otherwise, any PB-alginate interactions would 
have resulted in “disappearance” of the thermogram for PB, 
and new chemical bonding groups would have been detected 
on FTIR investigations.42,44 Hence, low affinity of PB for the 
alginate-matrix system of the microcapsules resulted in the 
drug preferentially partitioning onto the surface, forming 
crystal agglomerates that were viewed by SEM analysis and 
analytically verified via EDXR (Figures 4 and 5). Thus, future 
work will endeavor to study the stability and drug-release 
profiles at physiological conditions from these novel micro-
capsules and determine their feasibility as a delivery system 
for the effective oral administration of PB in T2D.
FTir spectral studies
The FTIR method is widely used to stimulate vibrational 





















































































Figure 6 Differential scanning calorimetric thermograms.
Notes: Probucol powder (A), sodium alginate powder (B), Probucol-sodium alginate microcapsule (C), and Probucol-sodium alginate powder (D). Probucol manufactured 
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Figure 7 Fourier transform infrared spectra.
Notes: Probucol powder (A), sodium alginate powder (B), Probucol-sodium alginate microcapsule (C), and Probucol-sodium alginate mixed powder (D). Probucol 
manufactured by sigma-aldrich co., st louis, MO, Usa.
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a variation in chemical reactions different to those in ther-
mal analysis, such as DSC. The FTIR spectra were used 
to confirm the chemical compatibility of PB with the SA 
polymer in the microencapsulation formulation. FTIR spec-
tra were analyzed for PB powder (Figure 7A), SA powder 
(Figure 7B), PB-SA microcapsules (Figure 7C), and PB-SA 
mixture (Figure 7D). FTIR spectral analysis of individual 
powders, mixed powders containing all the ingredients, and 
final microcapsules attained is necessary to ensure the chemi-
cal compatibility of PB postmicroencapsulation.
The spectrum of PB powder (Figure 7A) revealed charac-
teristic peaks at 2,959, 1,422, and 1,310 cm−1, which were in 
line with previously published work.44 In addition, the spec-
trum for SA powder (Figure 7B) was also in accordance with 
published work, revealing similar peaks.47
For the combined powder of PB-SA (Figure 7D), peaks 
representative of PB and the polymer were present with 
no interference, dilution, or alterations in the bond peak 
activity. This confirmed compatibility of all the ingredi-
ents in the powder form, which is the same combination/
proportions as formulated in the drug–polymer solution 
premicroencapsulation.
The FTIR spectra of the PB-SA microcapsule 
(Figure 7C) clearly showed two distinct and interference-
free peaks corresponding to PB (1,426 and 1,310 cm−1), 
with the third peak shadowed by the dominant infrared 
spectral activity of alginate in that region, and three distinct 
peaks representative of alginate (3,350, 1,602, and 1,025 
cm−1). As the DSC and FTIR results depicted no signifi-
cant changes in the chemical composition of SA or PB 
on microencapsulation, it seems valid to conclude that no 
chemical reaction or decomposition occurred before and 
after microencapsulation.
Overall, FTIR spectra of PB suggest that microencap-
sulation of PB with SA does not significantly compromise 
the chemical composition and structural integrity of the 
PB molecules because no significant chemical reaction 
occurred between the drug and any of the formulation 
excipients.
Conclusion
Using artificial cell microencapsulation, a novel form of tar-
geted drug delivery of PB with the polymer LVSA displayed 
optimal excipient compatibility and desired microcapsule 
size, uniformity, and homogeneity. An interesting future study 
will be to investigate the release profile, drug entrapment, 
and stability characteristics of this novel drug delivery for 
PB microcapsules.
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